Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-N neoadjuvant canakinumab and/or pembrolizumab in resectable NSCLC
jRCT2080225118Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Canakinumab monotherapy, Pembrolizumab monotherapy and Canakinumab + pembrolizumab (3 arms). Primary endpoint: Major pathologic response rate. Started Mar 2020; status: completed.
02
Drugs
canakinumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225118.